Solid Tumor Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer
Recruiting
  • Cancer
  • +3 more
  • Bintrafusp Alfa
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2021-10-14
Oct 14, 2021
V
Ph I/II Trial of Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC
Recruiting
  • Solid Tumor
  • +2 more
  • VSV-IFNβ-NIS
  • Pembrolizumab
  • Rochester, Minnesota
    Mayo Clinic
2021-10-07
Oct 7, 2021
S
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Biliary Tract Carcinomas
Active, not recruiting
  • Metastatic Cancer
  • Solid Tumor
  • Aurora, Colorado
  • +18 more
2021-10-13
Oct 13, 2021
M
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Recruiting
  • Solid Tumor
  • Advanced Breast Cancer
  • Milwaukee, Wisconsin
    Froedtert Hospital and the Medical College of Wisconsin
2021-10-13
Oct 13, 2021
S
Medical Treatment Decision Making Using Adaptive Conjoint Analysis - 2019
Terminated
  • Cancer
  • +4 more
    • Memphis, Tennessee
      St. Jude Children's Research Hospital
    2021-10-13
    Oct 13, 2021
    T
    A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
    Recruiting
    • Solid Tumor
    • +3 more
    • Nashville, Tennessee
    • +2 more
    2021-10-06
    Oct 6, 2021
    T
    A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer
    Not yet recruiting
    • Advanced Cancer
    • +2 more
    • (no location specified)
    2021-09-30
    Sep 30, 2021
    M
    Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
    Not yet recruiting
    • Solid Tumor
    • +9 more
    • MEM-288 Intratumoral Injection
    • (no location specified)
    2021-09-29
    Sep 29, 2021
    U
    INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies
    Recruiting
    • CNS Tumor
    • Solid Tumor
    • Nivolumab and Entinostat
    • Randwick, New South Wales, Australia
    • +11 more
    2021-10-12
    Oct 12, 2021
    M
    Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
    Recruiting
    • Solid Tumor
    • +2 more
    • CONVO intervention
    • New York, New York
    • +1 more
    2021-10-12
    Oct 12, 2021
    M
    Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
    Recruiting
    • Pharmacokinetics
    • +3 more
    • Mobile, Alabama
    • +13 more
    2021-10-12
    Oct 12, 2021
    N
    Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
    Recruiting
    • Metastatic Prostate Cancer
    • +4 more
    • M7824
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2021-10-12
    Oct 12, 2021
    D
    A Study of DT2216 in Relapsed/Refractory Malignancies
    Recruiting
    • Solid Tumor
    • Hematologic Malignancy
    • Chicago, Illinois
    • +2 more
    2021-10-05
    Oct 5, 2021
    S
    Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas - 2020
    Completed
    Has Results
    • Metastatic Cancer
    • +2 more
    • Grand Rapids, Michigan
    • +3 more
    2021-10-11
    Oct 11, 2021
    H
    IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
    Active, not recruiting
    • Metastatic Cancer
    • +8 more
    • Tampa, Florida
      H Lee Moffitt Cancer Center and Research Institute
    2021-10-07
    Oct 7, 2021
    C
    Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product - 2021
    Terminated
    • B Cell Lymphomas
    • +3 more
    • ACTR T Cell Product
    • Gilbert, Arizona
    • +15 more
    2021-10-04
    Oct 4, 2021
    C
    COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
    Recruiting
    • Endometrial Neoplasms
    • +3 more
    • COM701 in combination with BMS-986207 and nivolumab.
    • Chicago, Illinois
    • +6 more
    2021-10-03
    Oct 3, 2021
    E
    Study of E7389 Liposomal Formulation in Participants With Solid Tumor
    Recruiting
    • Solid Tumor
    • Kashiwa, Chiba, Japan
    • +10 more
    2021-10-01
    Oct 1, 2021
    P
    Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
    Recruiting
    • Solid Tumor
    • San Diego, California
      Rady Children's Hospital - San Diego
    2021-10-06
    Oct 6, 2021
    B
    Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141
    Not yet recruiting
    • Solid Tumor
    • BNT141
    • Duarte, California
    • +3 more
    2021-09-30
    Sep 30, 2021
    G
    To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
    Recruiting
    • Breast Cancer
    • Solid Tumor
    • Boston, Massachusetts
    • +12 more
    2021-10-05
    Oct 5, 2021
    R
    Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, a PARP Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors
    Recruiting
    • Solid Tumor
    • +6 more
    • Poznań, Poland
    • +2 more
    2021-10-05
    Oct 5, 2021
    M
    Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
    Recruiting
    • Rectal Adenocarcinoma
    • +4 more
    • Basking Ridge, New Jersey
    • +6 more
    2021-10-05
    Oct 5, 2021
    A
    Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
    Recruiting
    • Solid Tumor
    • Los Angeles, California
    • +6 more
    2021-10-04
    Oct 4, 2021
    B
    A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
    Recruiting
    • Solid Tumor
    • Scottsdale, Arizona
    • +17 more
    2021-10-04
    Oct 4, 2021